Opthea Ltd. Holds KOL Event for Sozinibercept
Ticker: OPTEY · Form: 6-K · Filed: Apr 3, 2024 · CIK: 1815620
Sentiment: neutral
Topics: biotech, drug-development, regulatory-filing
TL;DR
Opthea held a KOL event for sozinibercept in April 2024, details in new 6-K filing.
AI Summary
Opthea Limited filed a Form 6-K on April 3, 2024, to report on a Key Opinion Leader (KOL) event held in April 2024. The event focused on their drug candidate, sozinibercept, which is being developed for the treatment of retinal diseases. The filing includes a press release detailing the event.
Why It Matters
This filing provides insights into Opthea's ongoing development and promotional activities for sozinibercept, potentially impacting investor perception of the drug's future prospects.
Risk Assessment
Risk Level: medium — The filing relates to a clinical-stage biopharmaceutical company, which inherently carries higher risks due to the uncertainties of drug development and regulatory approval.
Key Players & Entities
- Opthea Limited (company) — Registrant
- sozinibercept (drug) — Drug candidate discussed at KOL event
- April 2024 (date) — Month of the KOL event and filing
- April 3, 2024 (date) — Filing date
FAQ
What is the primary purpose of the Form 6-K filing by Opthea Limited?
The primary purpose is to report on a Key Opinion Leader (KOL) event held in April 2024 concerning their drug candidate, sozinibercept.
What is the name of the drug candidate discussed at the KOL event?
The drug candidate discussed is sozinibercept.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on April 3, 2024.
What type of event was held in April 2024 that is being reported?
A Key Opinion Leader (KOL) event was held.
What is the principal executive office address of Opthea Limited?
The principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-04-03 06:06:29
Filing Documents
- opt_kol_presentation.htm (6-K) — 22KB
- opt-ex99_1.htm (EX-99.1) — 48KB
- opt-ex99_1s1.jpg (GRAPHIC) — 297KB
- opt-ex99_1s2.jpg (GRAPHIC) — 1112KB
- opt-ex99_1s3.jpg (GRAPHIC) — 426KB
- opt-ex99_1s4.jpg (GRAPHIC) — 464KB
- opt-ex99_1s5.jpg (GRAPHIC) — 304KB
- opt-ex99_1s6.jpg (GRAPHIC) — 252KB
- opt-ex99_1s7.jpg (GRAPHIC) — 283KB
- opt-ex99_1s8.jpg (GRAPHIC) — 349KB
- opt-ex99_1s9.jpg (GRAPHIC) — 490KB
- opt-ex99_1s10.jpg (GRAPHIC) — 345KB
- opt-ex99_1s11.jpg (GRAPHIC) — 318KB
- opt-ex99_1s12.jpg (GRAPHIC) — 313KB
- opt-ex99_1s13.jpg (GRAPHIC) — 366KB
- opt-ex99_1s14.jpg (GRAPHIC) — 416KB
- opt-ex99_1s15.jpg (GRAPHIC) — 383KB
- opt-ex99_1s16.jpg (GRAPHIC) — 308KB
- opt-ex99_1s17.jpg (GRAPHIC) — 231KB
- opt-ex99_1s18.jpg (GRAPHIC) — 418KB
- opt-ex99_1s19.jpg (GRAPHIC) — 388KB
- opt-ex99_1s20.jpg (GRAPHIC) — 323KB
- opt-ex99_1s21.jpg (GRAPHIC) — 448KB
- opt-ex99_1s22.jpg (GRAPHIC) — 319KB
- opt-ex99_1s23.jpg (GRAPHIC) — 427KB
- opt-ex99_1s24.jpg (GRAPHIC) — 362KB
- opt-ex99_1s25.jpg (GRAPHIC) — 303KB
- opt-ex99_1s26.jpg (GRAPHIC) — 315KB
- opt-ex99_1s27.jpg (GRAPHIC) — 279KB
- opt-ex99_1s28.jpg (GRAPHIC) — 370KB
- opt-ex99_1s29.jpg (GRAPHIC) — 473KB
- opt-ex99_1s30.jpg (GRAPHIC) — 405KB
- opt-ex99_1s31.jpg (GRAPHIC) — 432KB
- opt-ex99_1s32.jpg (GRAPHIC) — 301KB
- opt-ex99_1s33.jpg (GRAPHIC) — 252KB
- opt-ex99_1s34.jpg (GRAPHIC) — 360KB
- opt-ex99_1s35.jpg (GRAPHIC) — 325KB
- opt-ex99_1s36.jpg (GRAPHIC) — 305KB
- opt-ex99_1s37.jpg (GRAPHIC) — 423KB
- opt-ex99_1s38.jpg (GRAPHIC) — 308KB
- opt-ex99_1s39.jpg (GRAPHIC) — 203KB
- opt-ex99_1s40.jpg (GRAPHIC) — 381KB
- opt-ex99_1s41.jpg (GRAPHIC) — 418KB
- opt-ex99_1s42.jpg (GRAPHIC) — 325KB
- opt-ex99_1s43.jpg (GRAPHIC) — 385KB
- opt-ex99_1s44.jpg (GRAPHIC) — 203KB
- opt-ex99_1s45.jpg (GRAPHIC) — 426KB
- opt-ex99_1s46.jpg (GRAPHIC) — 230KB
- 0000950170-24-040648.txt ( ) — 23155KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 04/03/2024